Literature DB >> 28035205

Inhibition of Interleukin-12 and/or -23 for the Treatment of Inflammatory Bowel Disease.

Sands Bruce E1.   

Abstract

Entities:  

Year:  2016        PMID： 28035205      PMCID： PMC5193086     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  2 in total

Review 1.  New drugs on the horizon for IBD.

Authors:  Bruce E Sands
Journal:  Dig Dis       Date:  2014-12-17       Impact factor: 2.404

2.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Authors:  William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245
  2 in total
  2 in total

Review 1.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

2.  Gynostemma pentaphyllum saponins attenuate inflammation in vitro and in vivo by inhibition of NF-κB and STAT3 signaling.

Authors:  Wing-Yan Wong; Magnolia Muk-Lan Lee; Brandon Dow Chan; Victor Wan-San Ma; Wenchun Zhang; Timothy Tak-Chun Yip; Wing-Tak Wong; William Chi-Shing Tai
Journal:  Oncotarget       Date:  2017-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.